Woman from Central Texas thought she had allergies. Then she learned she had lung cancer, although she never smoked.

Telisotuzumab vedotin is under clinical development by AbbVie and currently in Pre-Registration for Non-Small Cell Lung Cancer.

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization ...

A Chinese player entered the U.S. non-small-cell lung cancer (NSCLC) arena as the U.S. FDA cleared Xcovery Holdings Inc.’s Ensacove (ensartinib) as a first-line therapy for adults with anaplastic ...

The latest announcement is out from AstraZeneca ( (AZN) ).

2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 ... Scientists Discover That Special ...

Fresolimumab is under clinical development by Sanofi and currently in Phase II for Non-Small Cell Lung Cancer.

Wendy Ketelsen knows how to paint a picture for people, especially about a challenging year that she never could have ...

A deep learning radiomic biomarker has been developed and validated to predict responses to immune checkpoint inhibitors in ...

A home-based exercise program boosted exercise capacity and quality of life among patients after lung cancer surgery but did not improve self-reported physical function, a new study found.

KB707 administered via inhalation demonstrated early evidence of monotherapy activity that was most pronounced in patients with advanced non-small cell lung cancer (NSCLC), where an objective response ...

The FDA has approved Xcovery Holdings' ALK inhibitor Ensacove for first-line treatment of adults with anaplastic lymphoma ...